We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.


Clear all

Refine your search

Content type

5 results found


Proskauer Rose LLP | USA | 6 Apr 2010

Implications for biotechnology enterprises and investors as district court invalidates cancer gene patents

Gene patent critics achieved a victory in a recent district court ruling having potentially far-reaching consequences for enterprises that use gene sequences to produce diagnostics, therapeutics, and other biotech products.

Previous page 1 Next page